MS
TBPH icon

Maven Securities’s Theravance Biopharma TBPH Stock Holding History

Maven Securities’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,342,574
Closed -$20.1M – 1265
2021
Q2 		$20.1M Buy
+1,342,574
New +$25.2M 0.81% 23

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Maven Securities's TBPH Position: Q3 2021 in Review

Maven Securities sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 1,342,574 shares — an estimated $20.1M sold.

Maven Securities first reported a position in TBPH in Q2 2021 and held it in 1 quarter. The position peaked at $20.1M in Q2 2021. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • Maven Securities reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 1,342,574 Theravance Biopharma shares in Q3 2021, an estimated $20.1M.
  • Maven Securities first reported a position in Theravance Biopharma in Q2 2021 and held it in 1 quarter.
  • Maven Securities's Theravance Biopharma position peaked at $20.1M in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.